Expertos Invitados





REVISION DE LAS DIFERENTES ALTERNATIVAS TERAPEUTICAS EN EL SINDROME CORONARIO AGUDO SIN ELEVACION DEL SEGMENTO ST

(especial para SIIC © Derechos reservados)
El tratamiento del síndrome coronario agudo consiste en la estabilización de la placa mediante tratamiento médico, el que puede ser seguido o no de coronariografía urgente según los casos.
jimenezmena9.jpg Autor:
Manuel Jiménez mena
Columnista Experto de SIIC

Institución:
Instituto de Cardiología, Hospital Ramón y Cajal

Artículos publicados por Manuel Jiménez mena
Coautores
Carlos Escobar Cervantes* Manuel Gómez Bueno** Asunción Camino López*** Javier Ortega*** 
Médico Residente de Cardiología, Instituto de Cardiología, Hospital Ramón y Cajal, Madrid, España*
Médico Adjunto de Cardiología, Servicio de Cardiología, Hospital Puerta de Hierro, Madrid, España**
Médico Adjunto de Cardiología, Instituto de Cardiología, Hospital Ramón y Cajal, Madrid, España***
Recepción del artículo
17 de Marzo, 2006 		Aprobación
30 de Marzo, 2006
Primera edición
22 de Mayo, 2007 		Segunda edición, ampliada y corregida
7 de Junio, 2021

REVISION DE LAS DIFERENTES ALTERNATIVAS TERAPEUTICAS EN EL SINDROME CORONARIO AGUDO SIN ELEVACION DEL SEGMENTO ST

Resumen
El término síndrome coronario agudo (SCA) se refiere a una manifestación de la enfermedad coronaria inestable y con riesgo para la vida. En concreto, incluye la angina inestable, el SCA sin elevación del segmento ST (SCASEST), el SCA con elevación del ST (SCAEST) y la muerte súbita cardíaca. Para los médicos de urgencias y para los cardiólogos representa un reto enorme la realización de un diagnóstico preciso con un tratamiento adecuado. En este artículo se revisa el manejo de los pacientes con SCASEST.

Palabras clave
síndrome coronario agudo, tratamiento


Artículo completo
(castellano)
Extensión:  +/-4.33 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

THERAPEUTIC CRITERIA IN ACUTE CORONARY SYNDROME

Abstract
The term acute coronary syndrome (ACS) refers to the unstable and life-threatening manifestations of coronary artery disease. In detail, it includes unstable angina pectoris, non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI) as well the sudden cardiac death. For emergency physicians and cardiologists alike, these patients represent an enormous challenge to accurately diagnose and appropriately treat. In this article we review the treatment for patients with NSTEMI.

Key words
acute coronary syndrome, treatment

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Cardiología
Relacionadas: Atención Primaria, Cuidados Intensivos, Farmacología, Medicina Familiar, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 4.33 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Manuel Jiménez Mena, Servicio de Cardiología, Unidad Coronaria, Hospital Ramón y Cajal, 28034, Carretera de Colmenar Viejo km 9,100, Madrid, España
Bibliografía del artículo
1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 4:1366-74.
2. Brian W, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, et al. Practical Implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the Emergency Department. Circulation 2005; 111:2699-2710.
3. Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet. 1988; 1:1088-1092.
4. Armstrong P. Stable ischemic syndromes: section 2: clinical cardiology (Califf RM, section ed). In: Topol EJ, ed. Textbook of Cardiovascular Medicine. Philadelphia, Pa: Lippincott-Raven; 1998:351-353.
5. White HD. Unstable angina: ischemic syndromes. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. Philadelphia, Pa: Lippincott-Raven; 1998:365-393.
6. Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiade M, Capone RJ, Crawford MH, Schlant RC, Kleiger RE, et al. Diltiazem and re-infarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med 1986; 315:423- 429.
7. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol 1987; 60:18A-25A.
8. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.
9. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). 1996; 348:1329-39.
10. Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale design and baseline characteristics including a metaanalysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000; 21:2033-41.
11. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527-33.
12. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349:1429-35.
13. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomised trial. Lancet 2001; 357:1915-24.
14. Zhao XQ, Theroux P, Snapinn SM, Sax FL. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: angiographic results from the PRISM-PLUS trial. Circulation 1999; 100:1609-15.
15. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339:436-43.
16. The SYMPHONY Investigators: Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Postacute Coronary Syndromes. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet 2000; 355:337-45.
17. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) Trial. Circulation 2000; 102:149-56.
18. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337:447-52.
19. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999; 100:1593-601.
20. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998; 97:2202-2212.
21. Flather M, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp- Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575-1581.
22. Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design [trial results presented at: American Heart Association Scientific Sessions; November 2003; Orlando, Fla]. Am Heart J 2000; 140:727-750.
23. López Bescós L (coordinador), Arós Borau F, Lidón Corbi RM, Cequier Fillat A, Bueno H, Alonso JJ, et al. Sociedad Española de Cardiología. Actualización (2002) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en angina inestable/infarto sin elevación del segmento ST. Rev Esp Cardiol 2002; 55(6):631-42.
24. FRISC Investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354:708-15.
25. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879-87.
26. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al, for the Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy (TAC-TICS)-TIMI 18 Investigators. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina an non-ST elevation myocardial infarction. JAMA 2001; 286:2405-12.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008